By Fineline Cube 
China-based HitGen Inc. (SHA: 688222) on Aug 27, 2025 released its semi‑annual financial results for the first half of 2025. The company posted RMB 227 million in revenue, a 16.58 % year‑on‑year increase, and a net profit attributable to shareholders of RMB 50.042 million, representing a 390.72 % jump versus the same period in 2024.
Key Financial Highlights
| Metric | 2025 H1 | YoY Change |
|---|---|---|
| Revenue | RMB 227 m | +16.58 % |
| Net Profit | RMB 50.042 m | +390.72 % |
| R&D Investment | RMB 28.8085 m | -3.09 pp (12.69 % of revenue) |
The company’s R&D spend fell slightly as a share of sales, reflecting a shift toward revenue‑generating commercial projects.
Platform‑Level Performance
| Platform | Revenue (RMB m) | YoY % |
|---|---|---|
| DEL (DNA‑Encoded Library) | 102.0 | +40.45 % |
| FBDD/SBDD (Fragment‑Based & Structure‑Based Design) | 65.24 | +4.15 % |
| OBT (Oligonucleotide‑Based Therapeutics) | 27.85 | -3.35 % |
| TPD (Targeted Protein Degradation) | 7.53 | -8.67 % |
| ChemSer (High‑Throughput Chemical Synthesis Services) | 18.72 | +94.17 % |
- DEL remains the cornerstone, delivering the largest revenue slice and the strongest growth.
- FBDD/SBDD benefited from milestone income from UK‑based Vernalis, reinforcing its steady trajectory.
- OBT saw a modest decline but continues to expand its monomer synthesis and one‑stop small‑nucleic‑acid projects.
- TPD is exploring new PROTAC‑based collaborations to offset the decline.
- ChemSer experienced a near‑doubling of revenue thanks to an efficient, automated synthesis platform.
Strategic Outlook
- Commercial Momentum – HitGen’s diverse platform mix is driving robust revenue growth, especially in DEL and ChemSer.
- Cost Discipline – R&D spend is being re‑balanced toward high‑yield projects while maintaining a strong innovation pipeline.
- Global Expansion – The company is positioning itself for broader international licensing and partnership opportunities, building on its UK subsidiary’s recent milestone payments.-Fineline Info & Tech